Find Perfluorohexyloctane manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 133331-77-8, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane, Perfluorohexyloctane, 7vyx4elwqm, Perfluorohexyloctane [who-dd], 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane
Molecular Formula
C14H17F13
Molecular Weight
432.26  g/mol
InChI Key
WRYIIOKOQSICTB-UHFFFAOYSA-N
FDA UNII
7VYX4ELWQM

Perfluorohexyloctane
1 2D Structure

Perfluorohexyloctane

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
2.1.2 InChI
InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
2.1.3 InChI Key
WRYIIOKOQSICTB-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCCCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F
2.2 Other Identifiers
2.2.1 UNII
7VYX4ELWQM
2.3 Synonyms
2.3.1 MeSH Synonyms

1. F6h8 Cpd

2. Perfluorhexyl-octan

3. Perfluorohexyl-octan

4. Perfluorohexyloctane

2.3.2 Depositor-Supplied Synonyms

1. 133331-77-8

2. 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane

3. Perfluorohexyloctane

4. 7vyx4elwqm

5. Perfluorohexyloctane [who-dd]

6. 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane

7. 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane F 6h8

8. Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-

9. Starbld0000620

10. Unii-7vyx4elwqm

11. 1-(tridecafluorohexyl)octane

12. Schembl890448

13. Dtxsid20440585

14. Mfcd07784188

15. Akos015911101

16. Zinc100046937

17. Bs-20913

18. Cs-0205555

19. A806597

20. J-006351

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 432.26 g/mol
Molecular Formula C14H17F13
XLogP38.7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count13
Rotatable Bond Count11
Exact Mass432.1122666 g/mol
Monoisotopic Mass432.1122666 g/mol
Topological Polar Surface Area0 Ų
Heavy Atom Count27
Formal Charge0
Complexity464
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding. 

Impressions: 10174

https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies

#PharmaFlow by PHARMACOMPASS
30 Jan 2025

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 133331-77-8 / Perfluorohexyloctane API manufacturers, exporters & distributors?

Perfluorohexyloctane manufacturers, exporters & distributors 1

15

PharmaCompass offers a list of Perfluorohexyloctane API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Perfluorohexyloctane manufacturer or Perfluorohexyloctane supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Perfluorohexyloctane manufacturer or Perfluorohexyloctane supplier.

PharmaCompass also assists you with knowing the Perfluorohexyloctane API Price utilized in the formulation of products. Perfluorohexyloctane API Price is not always fixed or binding as the Perfluorohexyloctane Price is obtained through a variety of data sources. The Perfluorohexyloctane Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Perfluorohexyloctane

Synonyms

133331-77-8, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane, 7vyx4elwqm, Perfluorohexyloctane [who-dd], 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane f 6h8

Cas Number

133331-77-8

Unique Ingredient Identifier (UNII)

7VYX4ELWQM

Perfluorohexyloctane Manufacturers

A Perfluorohexyloctane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Perfluorohexyloctane, including repackagers and relabelers. The FDA regulates Perfluorohexyloctane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Perfluorohexyloctane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Perfluorohexyloctane manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Perfluorohexyloctane Suppliers

A Perfluorohexyloctane supplier is an individual or a company that provides Perfluorohexyloctane active pharmaceutical ingredient (API) or Perfluorohexyloctane finished formulations upon request. The Perfluorohexyloctane suppliers may include Perfluorohexyloctane API manufacturers, exporters, distributors and traders.

click here to find a list of Perfluorohexyloctane suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Perfluorohexyloctane USDMF

A Perfluorohexyloctane DMF (Drug Master File) is a document detailing the whole manufacturing process of Perfluorohexyloctane active pharmaceutical ingredient (API) in detail. Different forms of Perfluorohexyloctane DMFs exist exist since differing nations have different regulations, such as Perfluorohexyloctane USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Perfluorohexyloctane DMF submitted to regulatory agencies in the US is known as a USDMF. Perfluorohexyloctane USDMF includes data on Perfluorohexyloctane's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Perfluorohexyloctane USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Perfluorohexyloctane suppliers with USDMF on PharmaCompass.

Perfluorohexyloctane GMP

Perfluorohexyloctane Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Perfluorohexyloctane GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Perfluorohexyloctane GMP manufacturer or Perfluorohexyloctane GMP API supplier for your needs.

Perfluorohexyloctane CoA

A Perfluorohexyloctane CoA (Certificate of Analysis) is a formal document that attests to Perfluorohexyloctane's compliance with Perfluorohexyloctane specifications and serves as a tool for batch-level quality control.

Perfluorohexyloctane CoA mostly includes findings from lab analyses of a specific batch. For each Perfluorohexyloctane CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Perfluorohexyloctane may be tested according to a variety of international standards, such as European Pharmacopoeia (Perfluorohexyloctane EP), Perfluorohexyloctane JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Perfluorohexyloctane USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty